HemaSphere (Jun 2022)
P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.
- G. Martinelli,
- A. Santoro,
- C. Gambacorti-Passerini,
- S. Vives Polo,
- S. R. Solomon,
- S. Mukherjee,
- E. Lech-Maranda,
- M. Yair Levy,
- A. Wierzbowska,
- M. Calbacho-Robles,
- G. Marconi,
- M. Benedetta Giannini,
- I. Cano,
- L. Torres Miñana,
- E. Acuña-Cruz,
- N. Angelosanto,
- A. Galleu,
- S. Baldini,
- S. Blotta,
- F. Ravandi,
- P. Montesinos
Affiliations
- G. Martinelli
- 1 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”-IRST S.r.l., Meldola
- A. Santoro
- 2 Department of Oncology, IRCCS, Humanitas Research Hospital
- C. Gambacorti-Passerini
- 3 Department of Hematology, University of Milano-Bicocca, Milan, Italy
- S. Vives Polo
- 4 Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Badalona, Spain
- S. R. Solomon
- 5 Northside Hospital Cancer Institute, Atlanta
- S. Mukherjee
- 6 Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America
- E. Lech-Maranda
- 7 Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- M. Yair Levy
- 8 Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, United States of America
- A. Wierzbowska
- 9 Department of Hematology, Medical University of Lodz, Lodz, Poland
- M. Calbacho-Robles
- 10 Department of Hematology, Ramón y Cajal University Hospital, Madrid, Spain
- G. Marconi
- 11 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST S.r.l., Meldola, Italy
- M. Benedetta Giannini
- 11 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST S.r.l., Meldola, Italy
- I. Cano
- 12 Department of Hematology
- L. Torres Miñana
- 13 Department of Hematology, La Fe University Hospital, Valencia, Spain
- E. Acuña-Cruz
- 12 Department of Hematology
- N. Angelosanto
- 14 13Clinical Development-Hematology, Ryvu Therapeutics, Krakow, Poland
- A. Galleu
- 15 Hematologic Malignancies - Global Oncology TA, Menarini Group, Florence, Italy
- S. Baldini
- 15 Hematologic Malignancies - Global Oncology TA, Menarini Group, Florence, Italy
- S. Blotta
- 15 Hematologic Malignancies - Global Oncology TA, Menarini Group, Florence, Italy
- F. Ravandi
- 16 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- P. Montesinos
- 17 La Fe University Hospital, Valencia, Spain
- DOI
- https://doi.org/10.1097/01.HS9.0000844968.45342.3d
- Journal volume & issue
-
Vol. 6
pp. 419 – 420
Abstract
No abstracts available.